Cerus Corporation
(Public, NASDAQ:CERS) Watch this stockFind more results for
CERS
Advertisement
Events
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -117.10% | -176.78% |
| Operating margin | -124.91% | -184.95% |
| EBITD margin | - | -181.01% |
| Return on average assets | -58.28% | -46.49% |
| Return on average equity | -119.25% | -77.64% |
| Employees | 107 | - |
Address
Website links
Company website:
http://www.cerus.com/
http://www.cerus.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Cerus Corporation discussed on blogs
Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 20, 2009
Cerus Corporation discussions
View all discussions »Description
Cerus Corporation, is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company markets the INTERCEPT system for both platelets and plasma in Europe and the Middle East. Cerus is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is in clinical development.
Officers and directors
| B. J. Cassin | Chairman of the Board | |
| Claes Glassell | President, Chief Executive Officer, Director | |
| Kevin D. Green | Principal Financial Officer, Chief Accounting Officer | |
| William M. Greenman | Senior Vice President - Business Development and Marketing | |
| Laurence M. Corash M.D. | Senior Vice President, Chief Medical Officer, Director | |
| Howard G. Ervin | Vice President - Legal Affairs | |
| Bruce C. Cozadd | Director | |
| William R. Rohn | Director | |
| Timothy Bruce Anderson | Director | |
| Gail Gaumer Schulze | Director |